Oscient responds to Factive CAP "approvable" letter
This article was originally published in Pharmaceutical Approvals Monthly
FDA has accepted Oscient's complete response to a September "approvable" letter for the antibiotic Factive (gemifloxacin), the firm announces Nov. 27. The claim for five-day treatment of community acquired pneumonia (CAP) has a new May 1 user fee date. The CAP sNDA was filed in November 2005 and given a standard review with a Sept. 21, 2006 user fee date. Factive is currently approved for five-day treatment of exacerbations of chronic bronchitis and seven-day treatment of CAP. The sNDA was supported by a single Phase III trial comparing five-day and seven-day treatment of acute bacterial sinusitis...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.